Project

A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI

Ongoing - recruitment active · 2023 until 2030

Früh Martin, Harder Anja, Quinter Janine